Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Silo Pharma Inc
(NQ:
SILO
)
1.490
+0.130 (+9.56%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Silo Pharma Inc
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More
April 17, 2024
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
April 11, 2024
Via
Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Plans for Exclusive Licensing of Novel Therapeutic for Alzheimer’s Disease
April 10, 2024
Via
Investor Brand Network
Silo Pharma set to Acquire Exclusive Licensing for Promising Alzheimer’s Disease Therapeutic
April 10, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Citizens And 2 Other Stocks Under $3 Insiders Are Buying
April 09, 2024
The Dow Jones index closed lower by around 10 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Silo Pharma And 3 Other Stocks Under $5 Insiders Are Buying
April 02, 2024
The Dow Jones index closed lower by over 200 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
March 30, 2024
Via
Benzinga
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
March 29, 2024
Via
Benzinga
Psyched: LSD, Psilocybin As Breakthrough Therapies, $14M Fed Grant For Ibogaine, Indiana's Research And More
March 20, 2024
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Exercises Option for Exclusive License Agreement for SPC-15
March 20, 2024
Via
Investor Brand Network
Exposures
Product Safety
Silo Pharma Exercises Option for Exclusive License Agreement for First-in-Class PTSD and Stress-Induced Anxiety Therapeutic
March 20, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Files Patent Application for Groundbreaking Ketamine Implant Therapeutic
March 18, 2024
Via
Investor Brand Network
Topics
Intellectual Property
Exposures
Intellectual Property
Silo Pharma Files Patent for Groundbreaking Ketamine Implant Therapeutic to Target Fibromyalgia and Chronic Pain
March 18, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
March 04, 2024
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
February 28, 2024
Via
Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Completes Successful Dose-Ranging Study in Advancement of SPC-15
February 28, 2024
Via
Investor Brand Network
Exposures
Product Safety
Silo Pharma Completes Successful Dose-Ranging Study of SPC-15 Intranasal Therapeutic for PTSD
February 28, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Psyched: Psychedelics & Sex, MDMA And Federal Approval, Canadians For End-Of-Life Care And More
February 15, 2024
Via
Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Announces Validation of Delivery System for SP-26
February 14, 2024
Via
Investor Brand Network
Silo Pharma’s SP-26 Ketamine Implant Demonstrates Successful Drug Delivery
February 14, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) to Prioritize Clinical Pipeline Targeting Mental Health, Chronic Pain and Neurology
February 01, 2024
Via
Investor Brand Network
Silo Pharma Announces Pipeline Prioritization for 2024 Targeting Mental Health, Chronic Pain, and Neurology
February 01, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Psyched: Suggestibility And Psychedelics' Effects, EU's $7M Research Fund, Australia's Treatment Delivery, BZ Podcast And More
January 27, 2024
New study finds suggestibility plays a role in antidepressant effects of psilocybin therapy. EU invests 6.5M euros in psychedelics for pulmonary disorder, MS, ALS, and Parkinson's. Australian...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
January 24, 2024
Via
Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Highlights Positive Results of Alzheimer’s Study
January 24, 2024
Via
Investor Brand Network
Silo Pharma Announces Positive Results in Alzheimer’s Disease Study
January 24, 2024
From
Silo Pharma, Inc.
Via
GlobeNewswire
Psyched: $100M For MDMA Therapy, VA Funds, 2024 Watchlist, Reform Updates And More
January 12, 2024
Psychedelics Developer Secures $100M In Series A Funding, Will Support MDMA Approval To Treat PTSD
Via
Benzinga
Psyched: Ibogaine For TBI, Kentucky Initiative Stalled, DEA Quotas, Insurance Codes, Atai's $50M And More
January 07, 2024
Ibogaine Therapy Shows Promising Outcomes For Veterans With Trauma Brain Injury
Via
Benzinga
InvestorNewsBreaks – Silo Pharma Inc. (NASDAQ: SILO) Successfully Completes First Phase of Dose-Ranging SPC-15 Study
January 04, 2024
Via
Investor Brand Network
Silo Pharma Concludes First Phase of Dose-Ranging Study Of Intranasal Treatment For Post Traumatic Stress Disorder
January 04, 2024
Thursday, Silo Pharma Inc (NASDAQ: SILO) provided an update on its previously announced dose-ranging study of SPC-15, a targeted prophylactic treatment for post-traumatic stress disorder (PTSD).
Via
Benzinga
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.